Artiva Biotherapeutics Sets 2026 Annual Meeting for Sept 8; Nomination Deadline Aug 1

What Happened

• Artiva Biotherapeutics, Inc. announced in an 8-K filed July 22, 2026 that its expected 2026 annual meeting of stockholders is September 8, 2026. Because that date is more than 70 days after the one-year anniversary of the 2025 annual meeting, the company’s amended and restated bylaws require advance notice from stockholders who wish to nominate directors or bring other business before the meeting.
• The filing was signed by CEO Fred Aslan, M.D.

Key Details

• Annual Meeting (expected): September 8, 2026.
• Deadline for stockholder notice to nominate or bring business: close of business on August 1, 2026.
• Deadline for stockholder proposals to be included in the company’s proxy statement under Rule 14a-8: close of business on August 1, 2026.
• Submission address: Artiva Biotherapeutics, Inc., Attention: Secretary, 5505 Morehouse Drive, Suite 100, San Diego, CA 92121. Notices/proposals must comply with the Bylaws and applicable Exchange Act rules.

Why It Matters

• If you are a stockholder planning to nominate a director or submit a proposal for inclusion in Artiva’s 2026 proxy materials, you must meet the August 1, 2026 deadlines and follow the company’s bylaw and SEC rule requirements to ensure your nomination or proposal will be considered and/or included. Failure to meet these timing or form requirements can prevent the company from recognizing the submission at the meeting.